On November 14, Amylyx Pharmaceuticals, Inc. shared findings from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial concerning avexitide, a novel glucagon-like peptide-1 (GLP-1) receptor antagonist. This study specifically targets post-bariatric hypoglycemia (PBH) in individuals who have undergone Roux-en-Y gastric bypass (RYGB) surgery.
Dr. Camille L. Bedrosian, chief medical officer at Amylyx, emphasized the importance of these results, stating they represent a major step toward addressing the persistent treatment gap for individuals suffering from PBH. The reported findings indicated a remarkable 55% reduction in the composite rate of self-monitoring of blood glucose (SMBG)-confirmed Level 2 and blinded Event Adjudication Committee (EAC)-adjudicated Level 3 hypoglycemic events when compared with a placebo. Specifically, the average event rate for the avexitide cohort was 0.55 events weekly versus 1.24 events for the placebo group (p=0.0000034).
LUCIDITY successfully met all key secondary endpoints, including a 63% reduction in SMBG-confirmed Level 2 events (p=0.0000032), a 47% drop in EAC-adjudicated Level 3 events (p=0.0016), and a 42% reduction in continuous glucose monitoring (CGM)-detected Level 2 events (p=0.00016) relative to placebo. In analysis tracking change from baseline, participants in the avexitide arm had a 72.9% decrease in events, while the placebo group showed a 37.8% reduction (p=0.000034 between arms).
Dr. Marilyn Tan, principal investigator, indicated that most trial participants experienced daily hypoglycemic symptoms at baseline, with many having a history of hospitalization related to hypoglycemia. The drop in these events could greatly alleviate the burden faced by patients. Avexitide was well tolerated, exhibiting a safety profile akin to earlier trials for PBH, mostly involving mild-to-moderate gastrointestinal and injection-site adverse events. Noteworthy is that there were no deaths or serious treatment-related adverse events reported during the trial.
On November 16, MiniMed announced the FDA clearance for MiniMed Fit™, a groundbreaking tubeless insulin pump designed for diabetes management. This device offers patients the ability to wear the pump for up to seven days, features a 300-unit insulin capacity, and incorporates app control alongside proven SmartGuard™ technology.
This innovative technology heralds a major expansion of MiniMed’s insulin delivery options, merging automated insulin delivery capabilities with a tubeless format. The extended wear duration of MiniMed Fit™ allows for fewer pump changes, relieving users from daily burdens related to diabetes management. Que Dallara, CEO of MiniMed, remarked on the balance between tubeless convenience and effective health outcomes for patients.
Key features of the MiniMed Fit™ include automated insulin adjustments every five minutes, ensuring responsive care, and Meal Detection™ technology that helps to avoid missed meal doses. Designed for flexibility, the device can be worn on various body parts, emphasizing compatibility with several types of insulins.
Plans for a phased rollout in the U.S. are underway, set to commence in spring 2027, signaling exciting new possibilities for diabetes care.
PolarityBio recently revealed that the FDA accepted its Biologics License Application (BLA) for SkinTE®, an innovative treatment for Wagner Grade 1 diabetic foot ulcers (DFUs). The acceptance came with a Priority Review designation, which entails a targeted action date of March 16, 2027, for a potentially expedited review process.
Dr. Nikolai Sopko, president and chief scientific officer at PolarityBio, highlighted the importance of the COVER DFUS II data package in demonstrating the urgent need for treatment options in patients with non-healing diabetic foot ulcers. This application follows the positive outcomes from their pivotal Phase III trial, which evaluated SkinTE against standard care, supporting the product’s potential impact on patient care in this area.